Go to Liminal BioSciences Q4 and Year-End Results Conference Call on Thursday March 25, 2021 8:30 AM EST
View NowOther content in this Stream

Liminal BioSciences Reports Fourth Quarter and Year End 2020 Financial Results
Liminal BioSciences Reports Fourth Quarter and Year End 2020 Financial Results

Liminal BioSciences Provides Update on Business Strategy and Focus on Small Molecule Therapeutics
LMNL focused on continued advancement of its small molecule therapeutics platform including development of fezagepras and evaluating strategic alternatives for its plasma-derived therapeutics entity.

Liminal BioSciences Receives FDA Approval for its US-based Plasma Collection Center
Prometic Plasma Resources (USA) Inc., has received U.S. Food and Drug Administration (“FDA”) approval for its plasma collection center located in Amherst, NY.

Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras
LMNL today announced that the first subject has been dosed in the Company’s fezagepras Phase 1 multiple ascending dose clinical trial in healthy volunteers.